Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial

Introduction As most patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) develop progressive disease after treatment with osimertinib, it is important to develop more effective treatment options. Afatinib has been shown to be more effective in in vitro stu...

Full description

Bibliographic Details
Main Authors: Nobuaki Kobayashi, Hisashi Hashimoto, Chisato Kamimaki, Ryo Nagasawa, Katsushi Tanaka, Sousuke Kubo, Seigo Katakura, Hao Chen, Nobuyuki Hirama, Ryota Ushio, Ayako Aoki, Kentaro Nakashima, Shuhei Teranishi, Saki Manabe, Hiroki Watanabe, Nobuyuki Horita, Keisuke Watanabe, Yu Hara, Masaki Yamamoto, Makoto Kudo, Hongmei Piao, Takeshi Kaneko
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:Thoracic Cancer
Subjects:
Afatinib
bevacizumab
EGFR
non‐small cell lung cancer
osimertinib
Online Access:https://doi.org/10.1111/1759-7714.13503

Internet

https://doi.org/10.1111/1759-7714.13503

Similar Items